According to a new study, people who face constant trouble trying to battle a migraine may find some relief in new drugs – drugs that do not come with any side effects.
Erenumab comes as a part of the new class of drugs —with human monoclonal antibodies that can block calcitonin gene-related peptide (CGRP) – a molecule responsible for transmitting migraine pain signals. The medication comes as a long-lasting injection which can stop a migraine even before it can start.
“If we can block CGRP, then we can abort a migraine attack,” said Dr David Kudrow, director of the California medical clinic for headache.
Today, more than 37 million Americans are under the influence of migraine attacks, as per American Headache Society. Of these, 37 million people, about 4 million suffer from chronic migraine which lasts up to 10 to 14 days a month.
Some people find help in low-cost drugs such as ibuprofen that are easily available. Many others need stronger medications like sumatriptan and ergotamine, which are also accused of constricting the blood vessels in the brain and result in nausea and dizziness – its potential side effects. Some of them use Botox injections to seek relief.
Moreover, a large number of people who suffer from migraines cannot find help in anything.
And this is when this new discovery can come to help.
“This is the first-ever mechanism specific migraine drug designed for prevention,” said lead study author Dr. Peter Goadsby, professor of neurology at Kings College London, UK and University of California, San Francisco. “This will change migraine treatment for those who don’t respond to conventional treatments.”
The drug is expected to receive FDA approval on May 17. If it is approved, one could purchase it for a prescription. The drug’s cost has been estimated at $10,000 a year.